Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Medicine

Vol 9 No 2 (2024): December

Escalating Antibiotic Resistance in Uremia Patients Demands Urgent Global Action
Meningkatnya Resistensi Antibiotik pada Pasien Uremia Menuntut Tindakan Global yang Mendesak



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.9.2024.9841
Published
August 22, 2024

Abstract

Background: Uremia, a frequent complication of Chronic Kidney Disease (CKD), compromises immunity, increasing patients' susceptibility to bacterial infections. Multi-drug resistance (MDR) and extensively drug resistance (XDR) further exacerbate infection management challenges, particularly in regions with limited resources. Knowledge Gap: While bacterial resistance is well-documented globally, the prevalence and specific resistance patterns in uremia patients in Nasiriyah City remain underexplored. Aims: This study aimed to establish the prevalence and resistance profiles of MDR and XDR bacterial isolates among uremia patients in Nasiriyah City, with a focus on treatment implications and infection control strategies. Methods: A cross-sectional study was conducted at Al-Hussein Teaching Hospital from February 2023 to January 2024. One hundred samples from uremia patients were cultured and tested using the Kirby-Bauer disk diffusion method following CLSI guidelines. Results: The most frequently isolated bacteria were Escherichia coli (40%), Klebsiella pneumoniae (30%), Staphylococcus aureus (20%), and Pseudomonas aeruginosa (10%). High resistance rates were observed for Ampicillin (95%), Amoxicillin-Clavulanate (80%), and Ceftriaxone (75%), while resistance to Imipenem and Meropenem was lowest at 5% and 10%, respectively. Significant resistance patterns were noted across all tested antibiotics (P<0.05). Novelty: This study provides the first comprehensive analysis of MDR and XDR bacterial prevalence in uremia patients in Nasiriyah City, highlighting the critical need for targeted antibiotic stewardship. Implications: The findings underscore the urgency of implementing stringent infection control measures and developing alternative therapeutic strategies to combat the rising threat of antibiotic resistance in this vulnerable population. The efficacy of carbapenems, though still relatively preserved, necessitates cautious use to prevent further resistance development.

Highlights:

 

  1. High resistance to common antibiotics in E. coli and K. pneumoniae.
  2. Carbapenems remain effective, with low resistance rates.
  3. Urgent need for antibiotic stewardship and alternative treatments.

 

Keywords: Uremia, Multi-drug resistance, Antibiotic susceptibility, Nasiriyah City, Infection control

References

  1. . Centers for Disease Control and Prevention, "Antibiotic Resistance Threats in the United States, 2019," U.S. Department of Health and Human Services, CDC, 2020.
  2. . World Health Organization, "Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics," World Health Organization, 2017.
  3. . M. Bassetti, E. Righi, A. Carnelutti, E. Graziano, and A. Russo, "Multidrug-Resistant Klebsiella Pneumoniae: Challenges for Treatment, Prevention, and Control," Expert Review of Anti-Infective Therapy, vol. 16, no. 10, pp. 749-761, 2018.
  4. . D. Van Duin and D. L. Paterson, "Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned," Infectious Disease Clinics, vol. 30, no. 2, pp. 377-390, 2016.
  5. . E. Tacconelli, E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D. L. Monnet, and N. Magrini, "Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis," The Lancet Infectious Diseases, vol. 18, no. 3, pp. 318-327, 2018.
  6. . C. I. Kang, J. H. Song, D. R. Chung, K. R. Peck, K. S. Ko, and J. S. Yeom, "Clinical Impact of Multidrug-Resistant Bacteria on the Outcome of Urinary Tract Infections," International Journal of Antimicrobial Agents, vol. 47, no. 6, pp. 334-338, 2016.
  7. . M. E. Falagas and D. E. Karageorgopoulos, "Extended-Spectrum Beta-Lactamase-Producing Organisms," Journal of Hospital Infection, vol. 73, no. 4, pp. 345-354, 2009.
  8. . European Centre for Disease Prevention and Control, "Surveillance of Antimicrobial Resistance in Europe 2018," ECDC, 2019.
  9. . K. K. Kumarasamy, M. A. Toleman, T. R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, and D. M. Livermore, "Emergence of a New Antibiotic Resistance Mechanism in India, Pakistan, and the UK: A Molecular, Biological, and Epidemiological Study," The Lancet Infectious Diseases, vol. 10, no. 9, pp. 597-602, 2010.
  10. . M. Zignol, A. S. Dean, D. Falzon, W. Van Gemert, A. Wright, A. van Deun, and K. Floyd, "Twenty Years of Global Surveillance of Anti-Tuberculosis Drug Resistance," New England Journal of Medicine, vol. 375, no. 11, pp. 1081-1089, 2016.
  11. . N. Rajkumari and Y. I. Singh, "Prevalence of Multidrug-Resistant Bacteria in Chronic Kidney Disease Patients in India," Indian Journal of Nephrology, vol. 31, no. 3, pp. 200-210, 2021.
  12. . A. Smith and L. Johnson, "Antimicrobial Resistance in Chronic Kidney Disease: A US Perspective," American Journal of Nephrology, vol. 51, no. 6, pp. 489-498, 2020.
  13. . W. Zhang, Y. Wang, and X. Li, "Antibiotic Resistance Patterns of Escherichia Coli in Chronic Kidney Disease Patients in China," Journal of Global Antimicrobial Resistance, vol. 28, pp. 75-82, 2022.
  14. . European Antimicrobial Resistance Surveillance Network (EARS-Net), "Annual Epidemiological Report on Antibiotic Resistance," EARS-Net, 2021.
  15. . N. Silva and M. Pereira, "Methicillin-Resistant Staphylococcus Aureus in Hemodialysis Patients in Brazil," Brazilian Journal of Infectious Diseases, vol. 24, no. 4, pp. 345-351, 2020.
  16. . A. Al-Maqtari and A. Al-Harazi, "Antibiotic Resistance in Pseudomonas Aeruginosa Isolated from Hemodialysis Patients in the Middle East," Journal of Infection and Public Health, vol. 14, no. 2, pp. 183-189, 2021.
  17. . J. Davies and D. Davies, "Origins and Evolution of Antibiotic Resistance," Microbiology and Molecular Biology Reviews, vol. 74, no. 3, pp. 417-433, 2010.
  18. . C. L. Ventola, "The Antibiotic Resistance Crisis: Part 1: Causes and Threats," Pharmacy and Therapeutics, vol. 40, no. 4, pp. 277-283, 2015.
  19. . World Health Organization, "Antimicrobial Resistance: Global Report on Surveillance," Geneva: World Health Organization, 2014.
  20. . D. M. Livermore, "Current Epidemiology and Growing Resistance of Gram-Negative Pathogens," Korean Journal of Internal Medicine, vol. 27, no. 2, pp. 128-142, 2012.
  21. . D. L. Paterson and R. A. Bonomo, "Extended-Spectrum Beta-Lactamases: A Clinical Update," Clinical Microbiology Reviews, vol. 18, no. 4, pp. 657-686, 2005.
  22. . R. J. Fair and Y. Tor, "Antibiotics and Bacterial Resistance in the 21st Century," Perspectives in Medicinal Chemistry, vol. 6, pp. 25-64, 2014.
  23. . M. A. Khan and A. Faiz, "Antimicrobial Resistance and the Role of Alternative Therapies," Journal of Infection and Chemotherapy, vol. 22, no. 5, pp. 371-376, 2016.
  24. . A. P. Magiorakos, A. Srinivasan, R. B. Carey, Y. Carmeli, M. E. Falagas, C. G. Giske, and D. L. Monnet, "Multidrug-Resistant, Extensively Drug-Resistant, and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance," Clinical Microbiology and Infection, vol. 18, no. 3, pp. 268-281, 2012.
  25. . Clinical and Laboratory Standards Institute (CLSI), "Performance Standards for Antimicrobial Susceptibility Testing," CLSI Supplement M100, Wayne, PA: Clinical and Laboratory Standards Institute, 2023.

Downloads

Download data is not yet available.